Cardinal Health forecasts lower earnings ahead

Shares of Cardinal Health slipped this morning after the drug distributor said that bigger investments and lower margins from vendors would leave it short of analysts' estimates for 2006 earnings. Analysts noted that the revision comes at a time that big distributors like Cardinal have been engineering a shift in the way they make money, ending an old practice of relying on drug inflation to provide profits. The wholesalers want to move toward a fee-based system with drug manufacturers.

- read this story from MarketWatch for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.